pazopanib

Molecular profiling leveraged IMmotion151 (A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma) trial data with whole-exome sequencing, RNA sequencing, and programmed cell death ligand 1 immunohistochemistry. Systemic standard of care treatments for mRCC, which include vascular endothelial growth factor receptor targeted therapy (VEGF-TT [sunitinib or pazopanib]), immune-oncology-VEGF (IO-VE [pembrolizumab and axitinib, pembrolizumab and lenvatinib, nivolumab and cabozantinib, or avelumab and axitinib]), and 2 IO (IO-IO [ipilimumab and nivolumab]) regimens...In this cohort study, the very favorable risk subgroup had a less immunogenic molecular profile and superior outcomes from VEGF-containing regimens (VEGF-TT and IO-VE) compared with the favorable risk group. The IO-IO combination showed significantly worse survival in this population, suggesting that VEGF inhibition remains essential for optimal outcomes.

Thirteen patients (46%) received recommended therapies, yielding disease control in eight (62%), including three long-lasting responses to pazopanib and trastuzumab deruxtecan, the latter administered based on ERBB2 overexpression in the absence of aberrant ERBB2 kinase activation. These findings demonstrate that multi-omics profiling provides clinically actionable insights for DSRCT management.

P1, N=54, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

Furthermore, several of the predicted candidate drugs (such as PAZOPANIB) have been previously reported to play a positive role in NSCLC treatment. This study highlights MVGAE as a novel computational framework for drug repurposing and demonstrates how its integration with complementary models can effectively prioritize potential therapeutic targets and candidate drugs, providing a robust computational basis for precision treatment strategies.

Immunoassays revealed that high-risk patients had 9 elevated immune checkpoints, while low-risk patients were more susceptible to pazopanib and temsirolimus. Real-time PCR (RT-qPCR) confirmed low levels of CASP7, PRKCB, and ENDOG mRNA in CRC tissues, with no significant difference between LMNB2 and GZMB. These findings highlight 5 MPTDN-associated prognostic genes in CRC, providing insights for individualized treatment and prognosis.

P1, N=15, Completed, The University of Sydney | Recruiting --> Completed

No partial responses (PR) were observed upon ipilimumab/nivolumab (0%), and pazopanib (0%). PRs were rare upon nivolumab (14%), sunitinib (25%), axitinib (28%) and axitinib/pembrolizumab (33%), but higher upon cabozantinib/nivolumab (50%) and cabozantinib in monotherapy (64%)...Based on this translational and clinical data, cabozantinib is the optimal systemic therapy for m-ccRCC patients with BrM. As the presence of BrM impacts the choice of first-line treatment, we advise to screen for BrM at baseline, even in asymptomatic patients.

P3, N=129, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027

P1, N=18, Not yet recruiting, M.D. Anderson Cancer Center

P2/3, N=140, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

Rutin, trifolin (a kaempferol glycoside), and epigallocatechin exhibited the strongest binding (e.g. rutin: - 8.85 kcal/mol to VEGF-A), surpassing the reference inhibitor Pazopanib (- 3.56 kcal/mol) with multiple stabilizing interactions with these proteins, suggesting potential to interfere with tumor angiogenesis and cell survival pathways. Collectively, these findings provide a scientific basis for the traditional use of T. globiferus and support its fraction as promising sources of multi-targeted anticancer agents. The identification of bioactive compounds further establishes a foundation for bioassay-guided isolation, mechanistic validation, and future drug development.

P1/2, N=51, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Aug 2026